RBC Capital Maintains Outperform on Biohaven, Raises Price Target to $23

Benzinga Newsdesk www.benzinga.com Positive 90.9%

Neg 0% Neu 0% Pos 90.9%

RBC Capital analyst Leonid Timashev maintains Biohaven (NYSE:BHVN) with a Outperform and raises the price target from $22 to $23.